FAQ on Oragenics Inc.'s Webinar About Concussion Drug Program ONP-002
Summary
What is the purpose of Oragenics Inc.’s webinar on May 20, 2025?
The webinar aims to provide a management update on Oragenics’ lead candidate, ONP-002, an intranasal therapy for mild traumatic brain injury, and discuss the unmet medical need in concussion treatment.
Who will be presenting at the webinar?
Presenters include CEO Janet Huffman, CMO Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock, a national emergency medicine expert.
What is ONP-002 and what stage is it in development?
ONP-002 is an intranasal therapy for mild traumatic brain injury, currently in a Phase IIa trial, with preclinical results showing promise in reducing brain inflammation and swelling.
Why is ONP-002 significant?
ONP-002 addresses an unmet medical need in concussion treatment, offering a potential new therapy for mild traumatic brain injury with promising early results.
How can I access more information about the webinar?
For more details, you can view the full press release at https://ibn.fm/YOy9Q or visit Oragenics’ website at www.Oragenics.com.
Where can I find the latest news and updates about Oragenics Inc.?
The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN.
What other areas is Oragenics Inc. focusing on besides concussion treatment?
Oragenics is also focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including treatments for Niemann Pick Disease Type C (NPC), and has proprietary powder formulation and an intranasal delivery device.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 114373